{
    "nct_id": "NCT03547115",
    "official_title": "Phase 1, Open-label, Study of Voruciclib in Subjects With Relapsed and/or Refractory B Cell Malignancies or AML After Failure of Prior Standard Therapies and Voruciclib in Combination With Venetoclax in Subjects With Relapsed/Refractory AML",
    "inclusion_criteria": "* Age ≥18 years\n* Histologically-confirmed diagnosis of Follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia(CLL), diffuse large B-cell lymphoma (DLBCL), or AML\n\n  a. Subjects must have disease that has relapsed or is refractory to 2 or more prior regimens and in need of treatment due to progressive disease\n* Presence of measurable disease defined per the 2008 International workshop on CLL guidelines, or by 2014 Lugano criteria for non-Hodgkin lymphoma (does not apply for AML subjects)\n* Adequate hematologic parameters unless clearly due to the disease under study\n* Adequate renal and hepatic function, per laboratory reference range at screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of pneumonitis of any cause\n* For CLL subjects: only known histological transformation to an aggressive lymphoma\n* For AML subjects:\n\n  1. Acute promyelocytic leukemia\n  2. Peripheral blast count > 25 × 10 9/L\n* Known central nervous system involvement\n* Significant cardiovascular disease\n* Significant screening ECG abnormalities\n* Subjects who require warfarin, anti-cancer therapeutics or investigational agents\n* Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) at the time of start of voruciclib therapy\n* Prior solid organ transplantation\n* Receipt of an allogeneic transplant within 6 months or an autologous transplant within the preceding 3 months; evidence of ongoing graft-versus-host disease (GVHD)\n* Prior therapy with a cyclin-dependent kinase (CDK9) inhibitor\n* Symptomatic/uncontrolled HIV infection/AIDS, or currently taking contraindicated medications for HIV control\n* Ongoing immunosuppressive treatment including calcineurin inhibitors at the time of the start of study treatment, including systemic or enteric corticosteroids except as follows:\n\n  1. Prior to the start of study treatment, subjects may be using systemic corticosteroids (≤20 mg/day of prednisone or equivalent), topical, or inhaled corticosteroids\n  2. During study therapy, subjects may use systemic, topical, or enteric corticosteroids, if needed",
    "miscellaneous_criteria": ""
}